• Dr. Mark Stein, Principal Investigator of the first-in-man trial will discuss the results of the first-in-human dose escalation study of oral ONC201 in advanced solid tumors at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, Massachusetts and will be published in the online Proceedings.

    Session ID:                           Poster Session C
    Session Title:                       New Molecular Targets
    Session Date and Time:      Sunday Nov 8, 2015 12:30 PM – 3:30 PM
    Location:                               Exhibit Hall C-D
    Permanent Abstract Number:  C137